You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoadjuvant Melanoma

Showing 1 - 25 of 5,424
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Stage III Trial in Shanghai (Toripalimab combined with Temozolomide)

Not yet recruiting
  • Melanoma Stage III
  • Toripalimab combined with Temozolomide
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 23, 2023

Melanoma Stage III Trial in North Sydney (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma Stage III
  • North Sydney, New South Wales, Australia
    Melanoma Institute Australia
Oct 26, 2022

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Stage II Melanoma Trial in Wollstonecraft (Relatlimab and nivolumab fixed dose combination (FDC))

Not yet recruiting
  • Stage II Melanoma
  • Relatlimab and nivolumab fixed dose combination (FDC)
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Oct 26, 2022

Mucosal Melanoma Trial in Wollstonecraft (Pembrolizumab, Lenvatinib)

Not yet recruiting
  • Mucosal Melanoma
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Sep 15, 2022

Merkel Cell Carcinoma Trial in Wollstonecraft (Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination)

Not yet recruiting
  • Merkel Cell Carcinoma
  • Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
  • Wollstonecraft, New South Wales, Australia
    Melanoma Institute Australia
Nov 21, 2023

Ocular Melanoma Trial in Sydney, Melbourne (Darovasertib)

Recruiting
  • Ocular Melanoma
  • Sydney, New South Wales, Australia
  • +1 more
May 3, 2022

Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin Trial in Marlborough (PH-762)

Not yet recruiting
  • Squamous Cell Carcinoma of the Skin
  • +2 more
  • Marlborough, Massachusetts
    Phio Pharmaceuticals Corp.
Aug 25, 2023

Melanoma Trial in Tampa (Tavo, Nivolumab, OncoSec Medical Electroporation Therapy System)

Recruiting
  • Melanoma
  • Tampa, Florida
    Moffitt Cancer Center
May 31, 2022

Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation Trial in Tampa (Encorafenib Pill, Binimetinib Pill, Nivolumab)

Recruiting
  • Melanoma Stage III
  • +2 more
  • Encorafenib Pill
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
May 27, 2022

Melanoma Trial in Salt Lake City (Nivolumab, HF10)

Terminated
Has Results
  • Melanoma
  • Salt Lake City, Utah
    Huntsman Cancer Institute
Jun 9, 2022

Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous

Recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +5 more
  • Jacksonville, Florida
  • +2 more
Oct 21, 2022

Melanoma, Melanoma Stage III Trial in New York (diagnostic test, drug, procedure)

Recruiting
  • Melanoma
  • Melanoma Stage III
  • PET Scan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Jun 24, 2022

Melanoma Trial in Charlottesville (Excision of clinically detected lymph node metastasis before any systemic therapy, Excision

Not yet recruiting
  • Melanoma
  • Excision of clinically detected lymph node metastasis before any systemic therapy
  • Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy
  • Charlottesville, Virginia
    Cancer Center at the University of Virginia
Apr 20, 2023

Melanoma Trial in Sydney, Wollstonecraft, Melbourne (Dabrafenib, Trametinib, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Sydney, New South Wales, Australia
  • +2 more
Apr 4, 2022

Cutaneous Melanoma Trial in Houston (Atezolizumab)

Recruiting
  • Cutaneous Melanoma
  • Houston, Texas
    Houston Methodist Hospital
Dec 28, 2021

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

Active, not recruiting
  • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

Melanoma, Squamous Cell Carcinoma of Head and Neck Trial (IO102-IO103, Pembrolizumab)

Not yet recruiting
  • Melanoma
  • Squamous Cell Carcinoma of Head and Neck
  • (no location specified)
Nov 7, 2022

Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in Australia, United States (TransCon IL-2 ß/?,

Recruiting
  • Advanced Solid Tumor
  • +7 more
  • TransCon IL-2 β/γ
  • +4 more
  • Boston, Massachusetts
  • +7 more
Nov 16, 2022

Melanoma Stage III, Melanoma Stage IV Trial in Washington, Boston, Pittsburgh (Dostarlimab (TSR-042) (singly), Dostarlimab

Recruiting
  • Melanoma Stage III
  • Melanoma Stage IV
  • Dostarlimab (TSR-042) (singly)
  • Dostarlimab (TSR-042) and TSR-022 (combination)
  • Washington, District of Columbia
  • +2 more
Feb 22, 2022

Pathologic Stage III Cutaneous Melanoma AJCC v8 Trial in United States (Imprime PGG, Pembrolizumab)

Withdrawn
  • Pathologic Stage III Cutaneous Melanoma AJCC v8
  • Imprime PGG
  • Pembrolizumab
  • La Jolla, California
  • +3 more
Oct 29, 2021

Melanoma Stage IIIB/C Trial in Spain, Switzerland, United States (Daromun, Surgery, Adjuvant therapy)

Recruiting
  • Melanoma Stage IIIB/C
  • La Jolla, California
  • +30 more
Dec 22, 2022

Melanoma, Lymph Node Cancer Trial in Pittsburgh (CMP-001, Nivolumab)

Active, not recruiting
Has Results
  • Melanoma
  • Lymph Node Cancer
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 15, 2022

Melanoma Trial in Pittsburgh (drug, biological, other)

Recruiting
  • Melanoma
  • Vidutolimod (CMP-001)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 25, 2022

Resectable Melanoma, Melanoma Stage III, Melanoma (Skin) Trial in Belarus, Russian Federation (BCD-217, anti-PD1, Excision of

Recruiting
  • Resectable Melanoma
  • +2 more
  • BCD-217
  • +3 more
  • Lesnoy, Belarus
  • +35 more
Feb 21, 2023